Cannabinoid · Endocannabinoid
Virodhamine is an endocannabinoid made by the body, in the N-acyl group. An endocannabinoid that is a partial CB1 agonist and CB2 agonist.
Where it fits
Virodhamine sits in the N-acyl group. See the Endocannabinoids index for how it relates to the rest of the family.
What the research shows
Direct human research on Virodhamine is minimal; it is characterised mainly by its chemistry and its place in the cannabinoid family rather than by clinical studies. We flag that plainly rather than overstate it.
Structural Chemistry and Dual CB1/CB2 Receptor Pharmacology
Virodhamine (O-arachidonoyl ethanolamine, molecular formula C22H37NO2, molecular weight 347.53 g/mol) is an endogenous arachidonic acid derivative discovered by Porter et al. in 2002 and named from the Sanskrit word virodha ("opposition"). Structurally, virodhamine is the constitutional ester isomer of anandamide (N-arachidonoyl ethanolamine, AEA): whereas anandamide links arachidonic acid to ethanolamine through an amide bond, virodhamine joins the two moieties through an ester linkage, leaving a free primary amine group. In mammalian tissues, virodhamine co-occurs with anandamide in the hippocampus, cortex, and peripheral organs, where peripheral tissue concentrations often exceed those of anandamide (Porter et al., 2002).
Pharmacologically, virodhamine exhibits opposing actions at the two classical cannabinoid receptors. At the CB2 receptor, it functions as a full efficacy agonist, whereas at the CB1 receptor it behaves as a partial agonist in vitro and acts in vivo as a functional CB1 antagonist or inverse agonist that attenuates anandamide-induced hypothermia (Porter et al., 2002). Beyond classical CB1 and CB2 receptors, virodhamine relaxes rat isolated mesenteric arteries via an endothelium-dependent atypical cannabinoid pathway sensitive to O-1918 (Ho & Hiley, 2004) and activates the orphan G-protein-coupled receptor GPR55 with nanomolar potency, stimulating intracellular calcium mobilization and beta-arrestin recruitment (Sharir et al., 2012).
Sources
- Porter AC, Sauer JM, Knierman MD, et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics, 301(3), 1020-1024. PMID 12023533
- Ho WS, Hiley CR (2004). Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. Journal of Pharmacy and Pharmacology, 56(7), 869-875. PMID 15233865
- Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME (2012). The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. Journal of Neuroimmune Pharmacology, 7(4), 856-865. PMID 22454039
FAQ
Is virodhamine intoxicating? No. Virodhamine is an endogenous lipid signaling molecule that acts as a functional antagonist at central CB1 receptors in vivo and does not produceTHC-like intoxication.
How does virodhamine differ structurally from anandamide (AEA)? Both share the formula C22H37NO2, but anandamide links arachidonic acid to ethanolamine via an amide bond, whereas virodhamine links them via an ester bond (O-arachidonoyl ethanolamine) with a free amino group.
Which receptors does virodhamine target in the body? Virodhamine acts as a full agonist at CB2 receptors, a partial agonist/functional antagonist at CB1 receptors, and a potent endogenous agonist at the orphan receptor GPR55.
Part of the NOIDS cannabinoids index. Educational reference, not medical advice.